Randall Urban, MD
Vice President for Research &
Chief Research Officer

Dr. Randall Urban

Dr. Randall Urban leads a diverse research community in the bold mission to improve medical practice through progressive translational research endeavors. He has 145 peer-review publications, is the Principal Investigator of UTMB's Clinical and Translational Science Award, and has 3 major research interests funded by the NIH and private foundations. In addition to Vice President for Research and Chief Research Officer, Dr. Urban is Vice Dean for Clinical Research in the John Sealy School of Medicine, Professor of Internal Medicine, Director of the Institute for Translational Sciences, and Fellow, John P. McGovern Distinguished Chair in Oslerian Medicine.

Strategic Research Plan

The Strategic Research Plan, which is used by leadership to  develop a path forward through goals, objectives and tactics, has broad input. It includes six integrated health communities that bring together researchers, educators, clinicians and community members to use prevention and treatment to transform illness to health. Read more.

Research Funding
Awards Processed
Lab Space
See more research facts and figures online





Quick, affordable model could predict severe COVID-19 cases

Researchers at the University of Texas Medical Branch have developed a quick and affordable model to predict if a COVID-19 patient will get a more severe case of the disease.

Identifying those patients at most risk can be done within the first 12 hours of hospital admission, researchers from the Infectious Disease Division at UTMB wrote in a study published in BMJ Open.

From a global perspective, the world needs this type of help, one of the study’s authors said.

“While the pandemic might be near an end in the United States, other places are not nearly through with COVID,” said John Davis, one of the authors who is a medical student in Population Health Sciences at UTMB. Davis is also the clinical education activities and operations director for St. Vincent's Clinics.

These other places with fewer resources don’t have effective vaccines and therapies, Davis said. They could benefit from an easy, fast assessment that would cost about $25 per person. That way, they could better allocate the resources they do have.

While researchers measured many variables in their study of 329 hospital patients, three factors stood out as the most consistent indicators of severe COVID-19: age, body mass index (BMI) and a blood test to measure lactate dehydrogenase (LDH). The higher all three of these indicators were, the worse the patient’s case of COVID progressed.

“We’re making it user-friendly so that you could go to MyChart and find the values to put in this model,” Davis said.

Even though the cases of COVID-19 have declined, the chance of a new variant surge is possible. This type of research—building models based on demographic and clinical data—can help the demand for healthcare when the next pandemic strikes, Davis said.